{"id":"cftr-modulators","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Upper respiratory tract infection"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This is achieved through the correction of the underlying genetic defect in cystic fibrosis, allowing for improved lung function and reduced risk of pulmonary complications. CFTR modulators have been shown to increase chloride ion transport and improve sweat chloride levels in patients with cystic fibrosis.","oneSentence":"CFTR modulators work by modifying the cystic fibrosis transmembrane conductance regulator protein to restore normal chloride ion transport across epithelial cell membranes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:25:41.623Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cystic fibrosis"},{"name":"Cystic fibrosis with a F508del mutation"}]},"trialDetails":[{"nctId":"NCT07442682","phase":"","title":"Characterisation of a Population of Adults Suffering From Cystic Fibrosis in a Belgian Reference Center","status":"ENROLLING_BY_INVITATION","sponsor":"Erasme University Hospital","startDate":"2025-12-11","conditions":"Quality of Lifte, Cystic Fibrosis (CF), Diabetes","enrollment":162},{"nctId":"NCT04732910","phase":"","title":"Modulate-CF: Cystic Fibrosis Transmembrane Regulator (CFTR) Biomarker Study to Evaluate the Rescue of Mutant CFTR in Patients With Cystic Fibrosis Treated With CFTR-modulators","status":"RECRUITING","sponsor":"Charite University, Berlin, Germany","startDate":"2018-07-01","conditions":"Cystic Fibrosis","enrollment":500},{"nctId":"NCT06515002","phase":"PHASE1, PHASE2","title":"A Study to Test How Well BI 3720931 is Tolerated and Whether it Improves Lung Function in People With Cystic Fibrosis (Lenticlair™ 1)","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2024-11-04","conditions":"Cystic Fibrosis","enrollment":5},{"nctId":"NCT03587961","phase":"EARLY_PHASE1","title":"Personalized Theratyping Trial","status":"RECRUITING","sponsor":"George Solomon","startDate":"2019-08-01","conditions":"Cystic Fibrosis","enrollment":20},{"nctId":"NCT04940533","phase":"","title":"Pharmacokinetics of CFTR Modulators in Pregnant Individuals and in Postpartum Breastfeeding Mothers","status":"NOT_YET_RECRUITING","sponsor":"University of Minnesota","startDate":"2027-01-01","conditions":"Cystic Fibrosis, Pregnancy","enrollment":30},{"nctId":"NCT07102043","phase":"","title":"Glucose Metabolism in Cystic Fibrosis Related Diabetes (CFRD)","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-04-01","conditions":"Cystic Fibrosis Related Diabetes","enrollment":30},{"nctId":"NCT04580368","phase":"NA","title":"Testing Drug Efficacy in Cystic Fibrosis Through N-of-1 Trials","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2021-05-01","conditions":"Cystic Fibrosis","enrollment":50},{"nctId":"NCT07289035","phase":"PHASE2","title":"Early Study on Tamoxifen Safety/Tolerability in Cystic Fibrosis Patients Unable to Use CFTR Modulators.","status":"NOT_YET_RECRUITING","sponsor":"Azienda Ospedaliera Universitaria Integrata Verona","startDate":"2026-01-15","conditions":"Cystic Fibrosis - Complete","enrollment":35},{"nctId":"NCT07031323","phase":"NA","title":"OnTrackCF: Engagement, Feasibility, and Acceptability Study","status":"RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2025-11-20","conditions":"Cystic Fibrosis (CF), Cystic Fibrosis - Complete","enrollment":60},{"nctId":"NCT03492567","phase":"NA","title":"Study of Circulating Blood Cell Monocytes as Predictive Biomarker of Bone Cystic Fibrosis Disease. Impact of CFTR Correctors.","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-04-25","conditions":"Cystic Fibrosis","enrollment":25},{"nctId":"NCT04828382","phase":"","title":"Prospective Study of Pregnancy in Women With Cystic Fibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amalia Magaret","startDate":"2021-09-30","conditions":"Pregnancy Related, Cystic Fibrosis","enrollment":285},{"nctId":"NCT06512064","phase":"NA","title":"Acoustic Waveform Respiratory Evaluation","status":"RECRUITING","sponsor":"Indiana University","startDate":"2024-07-23","conditions":"Asthma, COPD, Cystic Fibrosis","enrollment":800},{"nctId":"NCT04206436","phase":"","title":"CFTR Modulator Effects on Bone and Muscle in Adults With Cystic Fibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Indiana University","startDate":"2019-12-18","conditions":"Cystic Fibrosis, Bone Loss, Muscle Loss","enrollment":63},{"nctId":"NCT06797206","phase":"","title":"A Study of Females With CF Throughout Pregnancy and Post-partum, and Follow up of Their Offspring","status":"RECRUITING","sponsor":"Royal Brompton & Harefield NHS Foundation Trust","startDate":"2025-06-12","conditions":"Cystic Fibrosis (CF), Pregnancy, Infant, Newborn","enrollment":60},{"nctId":"NCT06504589","phase":"","title":"A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators","status":"RECRUITING","sponsor":"Nicole Hamblett","startDate":"2024-09-18","conditions":"Cystic Fibrosis","enrollment":400},{"nctId":"NCT07192679","phase":"","title":"MAGNIFY - Pulmonary Magnetic Resonance Imaging for Cystic Fibrosis","status":"RECRUITING","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2024-02-21","conditions":"Cystic Fibrosis (CF)","enrollment":80},{"nctId":"NCT05581056","phase":"","title":"Evaluation of the Evolution of Quality of Life in Relation to Naso-sinus Symptomatology Under Treatment With CFTE Modulators in Children Aged 6 to 11 Years With Cystic Fibrosis With Compatible Mutation","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2023-03-03","conditions":"Cystic Fibrosis","enrollment":27},{"nctId":"NCT05100823","phase":"NA","title":"Validation of Therapeutic Efficacy Targeting the Splicing Variants in Cystic Fibrosis and CFTR Pathologies","status":"TERMINATED","sponsor":"University Hospital, Montpellier","startDate":"2022-03-30","conditions":"Cystic Fibrosis, CFTR Gene Mutation","enrollment":16},{"nctId":"NCT04970225","phase":"NA","title":"Cystic Fibrosis Blood Neutrophils","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-07-08","conditions":"Cystic Fibrosis","enrollment":47},{"nctId":"NCT03506061","phase":"PHASE2","title":"Trikafta in Cystic Fibrosis Patients","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-09-04","conditions":"Cystic Fibrosis","enrollment":42},{"nctId":"NCT07048574","phase":"","title":"TIDES 2.0: Prevalence and Longitudinal Course of Depression, Anxiety, and Behavior Problems in Children With Cystic Fibrosis Under 12 Years of Age","status":"RECRUITING","sponsor":"State University of New York at Buffalo","startDate":"2025-06-02","conditions":"Cystic Fibrosis (CF)","enrollment":600},{"nctId":"NCT05519020","phase":"","title":"Inhaled Therapy Adherence and Outcomes to Kaftrio in Cystic Fibrosis","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2022-07-27","conditions":"Cystic Fibrosis","enrollment":1385},{"nctId":"NCT05802264","phase":"PHASE1","title":"Study to Assess Amphotericin B Cystetic for Inhalation (ABCI) Doses in Healthy Volunteers & People with Cystic Fibrosis","status":"RECRUITING","sponsor":"Cystetic Medicines, Inc.","startDate":"2023-03-21","conditions":"Cystic Fibrosis","enrollment":108},{"nctId":"NCT06350461","phase":"NA","title":"Impact of Discontinuing Hypertonic Saline in People With CF on Highly Effective CFTR Modulators- A SIMPLIFY Sub-Study","status":"COMPLETED","sponsor":"Nicole Hamblett","startDate":"2020-08-25","conditions":"Cystic Fibrosis","enrollment":370},{"nctId":"NCT06370962","phase":"","title":"Circadian Rhythm Disorders in Children With Cystic Fibrosis Under CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) Modulators","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2024-04-29","conditions":"Cystic Fibrosis","enrollment":180},{"nctId":"NCT05392855","phase":"NA","title":"Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF)","status":"TERMINATED","sponsor":"University of Missouri-Columbia","startDate":"2023-09-05","conditions":"Cystic Fibrosis, Mucociliary Clearance Defect","enrollment":6},{"nctId":"NCT05253859","phase":"","title":"CFTR Modulators and Gastrointestinal Complications","status":"COMPLETED","sponsor":"Nottingham University Hospitals NHS Trust","startDate":"2021-10-01","conditions":"Cystic Fibrosis, Gastrointestinal System Disease, Distal Intestinal Obstruction Syndrome","enrollment":47023},{"nctId":"NCT06284577","phase":"NA","title":"Quality of Life and Gut Health in Pediatric Patients With Cystic Fibrosis","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2024-01-02","conditions":"Cystic Fibrosis in Children","enrollment":40},{"nctId":"NCT06251622","phase":"","title":"Muscle Function and Physical Activity in the Modern Era of Cystic Fibrosis","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2024-02-19","conditions":"Cystic Fibrosis","enrollment":112},{"nctId":"NCT06322446","phase":"NA","title":"Exercise in People With Cystic Fibrosis on CFTR Modulator Therapy","status":"RECRUITING","sponsor":"Universidad Politecnica de Madrid","startDate":"2024-02-27","conditions":"Cystic Fibrosis","enrollment":48},{"nctId":"NCT02965326","phase":"NA","title":"Surrogate Markers of Response to New Therapies in Cystic Fibrosis Patients","status":"RECRUITING","sponsor":"Hôpital Necker-Enfants Malades","startDate":"2016-05","conditions":"Cystic Fibrosis","enrollment":75},{"nctId":"NCT06302270","phase":"","title":"CFTR Modulators in Pregnancy and Postpartum","status":"RECRUITING","sponsor":"Region Stockholm","startDate":"2024-03-15","conditions":"Cystic Fibrosis","enrollment":75},{"nctId":"NCT06184763","phase":"","title":"Evolution of the 6-minute Walk Test in Patients Treated With ELEXACAFTOR / TEZACAFTOR / IVACAFTOR","status":"UNKNOWN","sponsor":"Hospices Civils de Lyon","startDate":"2023-08-01","conditions":"Cystic Fibrosis","enrollment":73},{"nctId":"NCT04415268","phase":"NA","title":"Combined Effect of CFTR Protein Modulator Drugs and Exercise in Cystic Fibrosis","status":"WITHDRAWN","sponsor":"Universidad Europea de Madrid","startDate":"2020-06-09","conditions":"Cystic Fibrosis in Children","enrollment":""},{"nctId":"NCT04254705","phase":"NA","title":"Organoid Study R334W","status":"WITHDRAWN","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2020-03-01","conditions":"Cystic Fibrosis","enrollment":""},{"nctId":"NCT05726994","phase":"","title":"Volatilomic Approaches for the Study of CFTR Modulators (VOLATIL-CF)","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-02-06","conditions":"Cystic Fibrosis","enrollment":20},{"nctId":"NCT05699148","phase":"","title":"Gut Imaging for Function and Transit in Cystic Fibrosis 3 Junior","status":"UNKNOWN","sponsor":"Nottingham University Hospitals NHS Trust","startDate":"2022-04-01","conditions":"Cystic Fibrosis","enrollment":17},{"nctId":"NCT05663255","phase":"","title":"Effectiveness of CFTR Modulators According to Co-therapy","status":"UNKNOWN","sponsor":"Hospices Civils de Lyon","startDate":"2023-03-01","conditions":"Cystic Fibrosis","enrollment":1990},{"nctId":"NCT05200429","phase":"","title":"Canadian Observational Study Evaluating the Long-term IMPACT of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators on People With CF","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2021-11-01","conditions":"Cystic Fibrosis","enrollment":500},{"nctId":"NCT04215796","phase":"NA","title":"Evaluation of the ReX-C System, in Patients Receiving CFTR Modulators for the Treatment of Cystic Fibrosis (CF).","status":"UNKNOWN","sponsor":"Dosentrx Ltd.","startDate":"2020-05-12","conditions":"Cystic Fibrosis, Adherence, Medication","enrollment":10},{"nctId":"NCT04301856","phase":"","title":"Response to CFTR Modulators in CF Patients Under 18 Years","status":"UNKNOWN","sponsor":"Societe Francaise de la Mucoviscidose","startDate":"2020-01-01","conditions":"Cystic Fibrosis in Children","enrollment":600},{"nctId":"NCT04056702","phase":"","title":"Impact of Triple Combination CFTR Therapy on Sinus Disease.","status":"UNKNOWN","sponsor":"Jennifer Taylor-Cousar","startDate":"2019-09-05","conditions":"Cystic Fibrosis","enrollment":31},{"nctId":"NCT04623879","phase":"","title":"Real Life Evaluation of the Multi-organ Effects of Lumacaftor/Ivacaftor on F508del Homozygous Cystic Fibrosis Patients.","status":"COMPLETED","sponsor":"Carmel Medical Center","startDate":"2016-12-29","conditions":"Cystic Fibrosis","enrollment":13},{"nctId":"NCT01348204","phase":"PHASE2","title":"Nasal Potential Studies Utilizing Cystic Fibrosis Transmembrane Regulator (CFTR) Modulators","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2010-03","conditions":"Cystic Fibrosis","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1255,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Orkambi, Kalydeko...","EudraCT Number 2019-000833-37"],"phase":"phase_2","status":"active","brandName":"CFTR modulators","genericName":"CFTR modulators","companyName":"Hospices Civils de Lyon","companyId":"hospices-civils-de-lyon","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CFTR modulators work by modifying the cystic fibrosis transmembrane conductance regulator protein to restore normal chloride ion transport across epithelial cell membranes. Used for Cystic fibrosis, Cystic fibrosis with a F508del mutation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}